XALATAN
What it isProstaglandin analog that increases uveoscleral outflow; first-line treatment for open-angle glaucoma.
Why this oneGeneric and potent with less hyperemia than bimatoprost, it is the default first prostaglandin drop.
What limits itIris and periocular darkening can be permanent; eyelash growth and orbital fat loss alter appearance. Adherence often determines failure.
Read the full label on DailyMed ↗
| FDA dosing | Population | Start | Target | Max |
|---|---|---|---|---|
| Elevated IOP (open-angle glaucoma / ocular hypertension) | Adults | 1 drop affected eye(s) QHS (evening) | 1 drop QD (evening) | Once daily |
Renal Undefined
Hepatic Undefined
Exceeding once-daily dosing may reduce IOP-lowering effect or paradoxically raise IOP
Pregnancy No adequate studies; animal data show malformations and embryofetal lethality at clinically relevant doses
Lactation Undefined
NO BOXED WARNINGS
Principal riskPermanent iris darkening and eyelash changes
Cost, est. cash$10–$400/month
Generic entry2011
Legacy pregnancy categoryUnknown / historical label unavailable
Defining liabilityLocal irritation, sensitization or administration-site injury; negligible systemic toxicity at usual use.

Open Latanoprost in the interactive console ↗

